| Protocol | Description | USC Satellite Location |
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-15
Trial Leaders:
Jacob Thomas
| A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Treatment:
Immunotherapy
|
|
2N-20-6
Trial Leaders:
Jorge Nieva
| An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Treatment:
Biological Response Modifier
|
|
2N-23-5
Trial Leaders:
Robert Hsu
| A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer (HARMONi-3)
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
2O-22-1
Trial Leaders:
Jorge Nieva
| A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
2O-22-3
Trial Leaders:
Jorge Nieva
| PhI-135/ NCI 10445: Phase 1 Dose Escalation and Expansion Study of Tazemetostat in Combination of Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Treatment:
Chemotherapy: Systemic
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
2O-23-1
Trial Leaders:
Robert Hsu
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Treatment:
Other
| USC Koreatown, USC Newport Beach Oncology
|
NRG-CC009
Trial Leaders:
Jason Ye
| Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer
Treatment:
Radiation: External
|
|
NRG-LU008
Trial Leaders:
Jason Ye
| Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Treatment:
Radiation: External
|
|
SWOG-S1827
Trial Leaders:
Jason Ye
| MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Treatment:
Radiation: External
|
|
| Protocol | Description | USC Satellite Location |
0C-14-9
Trial Leaders:
Anthony El-Khoueiry
| A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies
Treatment:
Chemotherapy: Systemic
|
|
0C-18-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase I Study of FID-007 in Patients with Advanced Solid Tumors
Treatment:
Chemotherapy: Systemic
|
|
0C-18-21
Trial Leaders:
Diana Hanna
| A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-19-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Treatment:
(No treatments specified) |
|
0C-19-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with Balstilimab (AGEN2034), an Anti-PD1 Monoclonal Antibody, in Participants With Advanced Cancer
Treatment:
Immunotherapy
|
|
0C-20-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
| USC Newport Beach Oncology
|
0C-20-10
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
Treatment:
Other
|
|
0C-20-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies
Treatment:
Other
|
|
0C-20-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Treatment:
Other
|
|
0C-20-19
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Treatment:
Other
|
|
0C-20-22
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-24
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Treatment:
Immunotherapy
|
|
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors
Treatment:
Immunomodulator
|
|
0C-21-20
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-8
Trial Leaders:
Heinz Josef Lenz
| PhI-129 /NCI 10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
Treatment:
Other
|
|
0C-21-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Treatment:
Other
|
|
0C-22-11
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Study of BA3071 in Patients with Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-12
Trial Leaders:
Diana Hanna
| A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of Decoy20 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-15
Trial Leaders:
Jacob Thomas
| A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Treatment:
Immunotherapy
|
|
0C-22-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1B/2, Open-label Study of Q702 in combination with intravenous Pembrolizumab in Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-17
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-Label, First-in-Human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of SAR444200-Based Regimen in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-19
Trial Leaders:
Anthony El-Khoueiry
| First in Human Dose Escalation Study of AU409 in Patients with Advanced Primary Liver Cancers or Advanced Solid Tumor with Liver Predominant Metastatic Disease
Treatment:
Biological Response Modifier
|
|
0C-22-20
Trial Leaders:
Diana Hanna
| A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
|
|
0C-22-5
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Selected Advanced Solid Tumors with Cohort Expansions at the Recommended Phase 2 Dose
Treatment:
Immunotherapy
|
|
0C-23-1
Trial Leaders:
Jacob Thomas
| An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
Treatment:
Immunotherapy
Other
|
|
0C-23-10
Trial Leaders:
Jacob Thomas
| A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
Treatment:
Biological Response Modifier
|
|
0C-23-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-14
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
Other
|
|
0C-23-15
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-17
Trial Leaders:
Jacob Thomas
| Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma
Treatment:
Biological Response Modifier
|
|
0C-23-18
Trial Leaders:
Anthony El-Khoueiry
| A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-24
Trial Leaders:
Heinz Josef Lenz
| Phase I Study of Autologous CD8+ And CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown
|
0C-23-25
Trial Leaders:
Heinz Josef Lenz
| A Phase I/II, First-in-Human, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-26
Trial Leaders:
Jacob Thomas
| A Phase 1 Study of NM32-2668 (Anti-ROR1 / Anti-CD3/ Anti-HSA Tri- Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-23-5
Trial Leaders:
Anthony El-Khoueiry
| A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
Treatment:
Chemotherapy: Local
|
|
0C-23-6
Trial Leaders:
Jacob Thomas
| Phase 1 Clinical Study on the Tolerability of Utidelone Capsules in Patients with Advanced Solid Tumors
Treatment:
Other
|
|
0C-23-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors
Treatment:
Other
|
|
0C-23-8
Trial Leaders:
Syma Iqbal
| A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin18.2+ Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown, USC Newport Beach Oncology
|
0C-23-9
Trial Leaders:
Jacob Thomas
| Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0S-23-3
Trial Leaders:
Robert Hsu
| PhI-138 / NCI 10509: A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
